Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name AXL over exp
Gene Variant Detail

AXL over exp (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL over exp prostate cancer sensitive Bemcentinib + Metformin Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp prostate cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp head and neck cancer sensitive Bemcentinib + Erlotinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012). 24026012
AXL over exp lung non-small cell carcinoma predicted - sensitive SGI-7079 Preclinical - Cell line xenograft Actionable In a preclinical study, SGI-7079 inhibited growth of mesenchymal non-small cell lung cancer cell lines expressing high levels of AXL in culture and reduced tumor growth in xenograft models (PMID: 23091115). 23091115
AXL over exp Advanced Solid Tumor sensitive RXDX-106 Preclinical - Cell line xenograft Actionable In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells over expressing Axl in culture, resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...
AXL over exp triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). 27923843
AXL over exp head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment did not decrease proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture, and did not inhibit tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL over exp head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment in combination with Erbitux (cetuximab) synergistically inhibited proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture (PMID: 32439698). 32439698
AXL over exp head and neck squamous cell carcinoma sensitive Cetuximab + Imatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gleevec (imatinib) treatment in combination with Erbitux (cetuximab) synergistically inhibited tumor growth and induced regression in an Erbitux (cetuximab)-resistant cell line xenograft model of head and neck squamous cell carcinoma overexpressing AXL (PMID: 32439698). 32439698
AXL over exp melanoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment inhibited viability of a BRAF wild-type melanoma cell line overexpressing Axl in culture (PMID: 35332208). 35332208
AXL over exp lung non-small cell carcinoma resistant Osimertinib Preclinical - Cell culture Actionable In a preclinical study, non-small cell lung cancer cell lines overexpressing AXL were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 36681369). 36681369
AXL over exp lung non-small cell carcinoma sensitive Anlotinib + Osimertinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Anlotinib (AL-3818) and Tagrisso (osimertinib) inhibited proliferation and viability in Tagrisso (osimertinib)-resistant non-small cell lung cancer cell lines with overexpression of AXL in culture, and inhibited tumor growth in cell line xenograft models (PMID: 36681369). 36681369
AXL over exp adenoid cystic carcinoma predicted - sensitive Mecbotamab Vedotin Case Reports/Case Series Actionable In a Phase I trial, Mecbotamab Vedotin treatment resulted in stable disease with radiological and clinical improvement in a patient with adenoid cystic carcinoma with high AXL expression (PMID: 38579194; NCT03425279). 38579194